Home/Pipeline/LioCyx‑M (LTCR‑H3‑4)

LioCyx‑M (LTCR‑H3‑4)

Advanced primary HBV‑related HCC

Phase 1b/2Active

Key Facts

Indication
Advanced primary HBV‑related HCC
Phase
Phase 1b/2
Status
Active
Company

About Lion TCR

Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.

View full company profile